Vildagliptin: the first innovative DDP-4 inhibitor | Zendy

Edvin Villkhauer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Vildagliptin: the first innovative DDP-4 inhibitor

Author(s) -

Edvin Villkhauer

Publication year - 2010

Publication title -

diabetes mellitus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.155

H-Index - 12

eISSN - 2072-0378

pISSN - 2072-0351

DOI - 10.14341/2072-0351-5499

Subject(s) - vildagliptin , sitagliptin , dipeptidyl peptidase 4 , medicine , pharmacology , dipeptidyl peptidase , dipeptidyl peptidase 4 inhibitor , type 2 diabetes mellitus , saxagliptin , type 2 diabetes , diabetes mellitus , endocrinology , enzyme , biochemistry , chemistry

A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presentedalong with the results of its comparison with another agent of this group (sitagliptin).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research